Abstract: A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.

Abstract: A composition and an associated method of treating cancer cells by impeding cancer cell growth with the composition are disclosed. The composition includes at least a first and a second HMG-CoA reductase inhibitor, wherein the total amount of the first and second HMG-CoA reductase inhibitors is effective in synergistically impeding cancer cell growth and wherein the cancer cell growth synergistic impedance from the total amount of the first and second HMG-CoA reductase inhibitors is greater than a theoretical additive effect from the combined first and second HMG-CoA reductase inhibitors. The present composition does not simultaneously contain both a tocotrienol and an ionone when the composition contains only a first and a second HMG-CoA reductase inhibitor. The method includes treating cancer cells with the claimed composition to impede cancer cell growth.

Abstract: A method of and compositions for suppressing the growth of tumor cells in a patient are disclosed. In one embodiment, the method comprises treating the patient with an effective amount of an isoprenoid ether-linked compound, wherein the isoprenoid ether-linked compound comprises a first acyclic isoprenoid molecule linked via an ether linkage to a second molecule, wherein the second molecule can suppress tumor formation.

Abstract: A method of inhibiting the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones.

Abstract: A method of and compositions for suppressing the growth of tumor cells in a patient are disclosed. In one embodiment, the method comprises treating the patient with an effective amount of an isoprenoid ether-linked compound, wherein the isoprenoid ether-linked compound comprises a first acyclic isoprenoid molecule linked via an ether linkage to a second molecule, wherein the second molecule can suppress tumor formation.

Abstract: A method of inhibiting or preventing the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of administering a compound selected from the group consisting of citracetal, citral dimethyl acetal, citral diethyl acetal, geranyl benzoate, geranyl tiglate, geranyl anthranilate, farnesyl benzoate, farnesyl anthranilate, farnesyl tiglate, farnesyl acetate and combinations thereof to a human tumor patient, wherein the amount is effective to reduce or inhibit tumor growth by at least 50%.

Abstract: A method of inhibiting the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones.

Abstract: A method for causing regression of a leukemia cell tumor is disclosed. This method comprises the step of administering perillyl alcohol to a tumor-containing mammal.

Abstract: A method of causing carcinoma regression is disclosed. One administers an effective amount of perillic acid methyl ester. The use of perillic acid methyl ester is disclosed. A pharmaceutical composition involving perillic acid methyl ester is disclosed.

Abstract: A method for causing regression of a carcinoma is disclosed. This method comprising the step of administering to a carcinoma-containing mammal an effective amount of a compound of the formula: ##STR1## This formula represents perillyl alcohol.

Abstract: A method of lowering cholesterol comprises administering to an animal safe and effective amounts of d-.alpha.-tocotrienol. A method of extracting d-.alpha.-tocotrienol from natural sources and pharmaceutical compositions containing d-.alpha.-tocotrienol are also disclosed.